Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...

(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish ...

Tecfidera (dimethyl fumarate) is a prescription drug that’s used to treat certain types of multiple sclerosis. The drug comes as a delayed-release oral capsule. Tecfidera may not be safe to take while ...

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continued this week with a court ruling that clears the way for more ...

On September 2, 2015, the USPTO Patent Trial and Appeal Board (PTAB) denied institution of another Inter Partes Review brought by Kyle Bass, the Coalition for Affordable Drugs, and other related ...

Biogen’s contingency plan to keep Tecfidera generics at bay has fallen flat. After a U.S. appeals court in November declined to resurrect a key patent on Biogen’s multiple sclerosis (MS) blockbuster ...

Warehoused patients, months of Wall Street hype, and positive clinical data all added to the anticipation around Biogen Idec’s Tecfidera MS drug. Months following launch, this Cinderella story—of a ...

The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...

The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by ...

Biogen Idec’s newest drug for multiple sclerosis has now brought in revenues of $854 million in its first nine months on the market, and may be the first drug ever to reach blockbuster status in its ...

For a brief moment, there was significant investor anxiety that the 'holy mother' of all drug launches might burst like a balloon. A report that the new Tecfidera multiple sclerosis pill was possibly ...